ClinicalTrials.gov
public full text
Public Domain
Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)
Phase II trial to study the effectiveness of gefitinib in treating patients who have advanced unresectable hepatocellular carcinoma (liver cancer). Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis#863246
- Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery#837346
- Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery#1096382
- Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma#1138373
- A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)#1173801
Record · ID 1184488
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive